Introduction
Familial hypercholesterolemia (FH) is characterized by hypercholesterolemia, xanthomas, and premature coronary heart disease (CHD) and affects around 1 in 500 people in western countries 1, 2 . It is a monogenic disorder caused by mutations in three genes: those coding for the receptor for low density lipoprotein (LDL) particles (LDLR), for apolipoprotein B (APOB) and for an enzyme involved in the degradation of the receptor as it recycles, PCSK9 3 .
Treatment with statins is effective and reduces mortality 4, 5 . In the UK less than 15% of the predicted 110,000 affected people are diagnosed 6 . FH is diagnosed in the UK using the Simon Broome Criteria 2,7 based on cholesterol levels (typically the ninety-fifth percentile of total serum cholesterol or LDL-cholesterol (LDL-C) is a cut-off value), family history of hyperlipidaemia or early CHD, and presence of (or family history of) xanthomas. Individuals fulfilling these criteria, and those found to carry an FHcausing mutation are given the diagnosis of definite FH (DFH), while those showing only elevated cholesterol levels together with a family history of hyperlipidaemia or early CHD are given the diagnosis of possible FH (PFH).
There is considerable overlap in the distribution of LDL-C levels between individuals with and without FH. In children, where the overlap is least 8, 9 , using a simple cut off results in a false positive rate of 8-10% and a false negative rate of 10-15%. In adults, the false negative is greater 10 . Also, an individual"s cholesterol levels may fluctuate, moving from below to above the cut-off value on repeat measurements. Thus, some patients will be given a false negative diagnosis (i.e. told that they do not have FH when they do), while others will be given a false positive diagnosis (told that they have FH when they do not).
When DNA testing is used to diagnose FH, a mutation can be identified in 60-90% of DFH patients 11, 12 , depending on the sensitivity of the methods and the population under consideration. By comparison, a mutation can be identified in only 20-30% of PFH patients 13, .
Once the underlying mutation has been identified, molecular genetic screening of first degree relatives has a sensitivity and specificity close to 100%.
The UK National Institute for Health and Clinical Excellence (NICE) has recommended, based on deterministic economic evaluation of the alternative approaches to cascade screening 14, 15 , the use of "cascade screening" of first degree relatives of patients with FH using cholesterol measurement and DNA methods in combination. This paper presents the results of a probabilistic economic analysis to compare the costs and benefits of alternative screening strategies in terms of quality adjusted life years (QALYs).
Methods

Model structure, assumptions and analytical methods
We constructed a decision tree in Excel™ where a hypothetical 1000 patients referred from general practice with a suspicion of heterozygous FH entered the model. Figure 1 shows a schematic presentation of the decision problem and a full breakdown of the decision pathways. The decision pathways for all the methods under consideration each have three disease states which depict the initial diagnosis i.e. definite FH, possible FH and not FH, as defined by the Simon Broome 7 and the FHCAP study 16 . Subsequent branches of the tree are dependent on the cascade screening method under consideration which are described in detail below. Once individuals are identified as true positives (TP), false positives (FP), true negatives (TN) and false negatives (FN) at the end of the decision tree, they enter into a
Markov model according to the treatment protocol also described below. Four cascade screening methods were compared:
1. The cholesterol method: This is the standard method of clinical diagnosis and identification of affected relatives using elevation of LDL-C levels. Only patients meeting the criteria of DFH or PFH were included for cascade testing.
2. The DNA method: The identification of an FH-causing mutation by molecular genetics methods, firstly in the index patient and then in first degree relatives. Only patients with an identified FH-causing mutation were included for cascade testing.
3. The DNA+DFH method: Following DNA testing of the index cases cascade testing of relatives is undertaken in all mutation-positive index cases but additionally, in the relatives of DFH index cases where no mutation can be found, cascade testing is undertaken using cholesterol (LDL-C) levels to identify affected relatives 4. The DNA+DFH+PFH method: Following DNA testing of the index cases cascade testing of relatives is undertaken in all mutation-positive index cases but additionally, in the relatives of DFH and PFH index cases where no mutation can be found, cascade testing is undertaken using cholesterol (LDL-C) levels to identify affected relatives.
Treatment protocol and estimated long-term benefits from statin treatment.
All index cases and relatives with a diagnosis of FH (whether DFH or PFH) are assumed to be offered high intensity statin therapy, in line with NICE guideline on FH 14, while true and false negatives were assumed to be on low intensity statin. For the relatives, a proportion (1.3%) given high intensity statin but did not benefit from the statin, rather they incurred a disutility
(reduction in quality of life) estimated to be about 3% and then varied in sensitivity analysis (Expert opinion). We developed a Markov model using Microsoft™ Excel to estimate the treatment benefit from statins. The structure of the model is described in detail previously 1818 , and used data from the Simon Broome Study 7, 1919 . Death from other causes was assumed to be the same as that of the general population and was taken from the life tables of the England . All costs were at 2009 2010/11 prices and as per current NICE guidance; an annual discount rate of 3.5% was used for both costs and health benefits.
Outcomes and quality of life (Utility):
Clinical outcomes modelled were myocardial infarction, stroke, heart failure, transient ischaemic attack; peripheral arterial disease, unstable angina, revascularisation, cardiovascular and total mortality. Utility weights for the various health states and age adjusted utility from were taken from our earlier study 1818 . Age adjusted utility was solicited from the general population using time trade off 30 30 (see supplementary table Table 2 Due to imperfect information on the effectiveness of intervention and the resources consumed for treatment, both the costs and effects of health interventions are inevitably associated with some degree of uncertainty, and this introduces the possibility of error into decision-making 2932 . In our analysis we used Monte Carlo simulation to generate the sampling distribution of the joint mean cost and efficacy in order to quantify the uncertainty around the estimates of costs and effects. In addition we also did one-way sensitivity analysis on variables which had uncertain estimates and yet were likely to influence overall conclusions. These included the cost of the cholesterol method, a reduction in the cost of statins, any potential loss in quality of life due to side effects of high dose statins and the costs of DNA testing.
Results
The four cascade screening methods identified differing numbers of true and false negatives and positives amongst both cases and relatives ( Table 1 ). The DNA only strategy required the least number of relatives to be tested, but did not identify as many true positives as the DNA+DFH+PFH strategy. This last strategy was also the strategy that required the largest number of relatives to be screened. Table 2 shows the cost of diagnosis and treatment of people diagnosed with either monogenic or polygenic hypercholesterolaemia for each of the four strategies, using the treatment protocol outlined above in the methods section, while Table 3 
Costs of diagnosis and treatment
Cost effectiveness
As shown in Table 4 , all DNA based methods were cost-effective relative to the cholesterol only method. However, cascade testing from DNA+DFH is ruled out by extended dominance.
The principle of extended dominance is applied in incremental cost-effectiveness analyses to eliminate from consideration strategies whose costs and benefits are improved by a mixed strategy of two other alternatives 31 alternatives 33 . Thus the combinations of DNA only and DNA+DFH+PFH are both more cost-effective than DNA+DFH. After accounting for the options ruled out by extended dominance, the relevant incremental comparison is between the DNA method and the DNA+DFH+PFH method. The estimated base case incremental costeffectiveness ratio (ICER) is £3,666/QALY, as shown in Table 4 .
We assessed uncertainty around this ICER by Monte-Carlo simulation using 2000 iterations. Figure 2 illustrates the probability that any one strategy is cost-effective, as a function of the willingness to pay. Given a maximum acceptable ceiling ratio of £20,000/QALY the probability that DNA+DFH+PFH is cost-effective compared to the DNA method is 100%.
Thus, given the data, there is a 100% chance that the additional cost of DNA+DFH+PFH, compared with the DNA method, is at or below £20,000 per QALY gained.
One way sensitivity analysis showed that the model results were not sensitive to changes in assumptions about loss in quality of life due to side effects of high dose statins as the ICERs remained below £20,000/QALY when the assumption was varied between 1% and 10%.
We also varied the cost of statins as we expect atorvastatin to be off patent in 2011. We thus reduced the cost of atorvastatin by 60% and the cost-effectiveness results became more favorable with the ICER falling from the current estimate of £3,666 to £3,070/QALY. We also varied other variables like the proportions of index cases and relatives who agreed to testing, the age at identification for index cases and relatives, and the cost of cholesterol testing and DNA costs, and in all cases the ICERs remained below £4,000/QALY, suggesting the model is not sensitive to changes in these parameters. The base model assumed that there was no quality of life loss associated with side effects of statins, and when we assumed a 5% loss in quality of life the ICER increased only slightly to £4,028 demonstrating that the model results are also not sensitive to this assumption.
Discussion
Our economic analysis indicates that the most cost-effective cascade screening strategy for people suspected of Familial Hypercholesterolaemia is DNA testing plus cascading from both mutation negative definite and possible FH individuals, with an estimated ICER of £3,666/QALY when compared to the DNA only method. Our results were stable in univariate sensitivity analysis. Probabilistic sensitivity analysis also showed that the DNA+DFH+PFH strategy is 100% cost-effective as it falls below the recommended £20,000/QALY threshold currently used in the UK for evaluating interventions. Altering assumptions about several key determinants of cost and effectiveness including the cost of statins (which will fall in the near future as some of the potent statins recommended for FH patients come off-patent), the cost of DNA testing, the overall cost of the cholesterol measures, the proportions of index cases and relatives who agreed to testing, and the age at identification for index cases and relatives did not materially influence the ICERs. There is no uncertainty that DNA+DFH +PFH is the most cost-effective option.
Strengths and weaknesses
To our knowledge this is the first probabilistic analysis of FH screening strategies for the UK.
Because patients with FH have very high LDL-C levels from birth, they will frequently require high intensity lipid lowering therapy sufficient to reduce LDL-C to recommended levels 14, 15 and studies have shown that statin treatment reduces their premature mortality 5 . In our model we have used a combination of statins but the model was not sensitive to different combinations of statins. We have assumed that any individual identified with elevated LDL cholesterol levels will be treated whether or not they carried the family mutation. Individuals who do not carry the mutation are likely to be treated with a lower dose of statin and the costs and benefits for this have been included in the model. The results of our model were not sensitive to the documented side effects of statins 32 34,35 since variations in screening methods influence numbers of people allocated to high or low dose, but have no influence on the QALY gain from the statin treatment.
Because observational data from the Simon Broome Register cohort showed no significant increase in mortality in FH patients over 60 years old 4 , we have assumed that people over the age of 60 will benefit from statins to the same degree as the general population. This does not support ceasing treatment at age 60 in people diagnosed with FH. People with FH who have reached this age or beyond without treatment and without experiencing any cardiovascular event or symptoms appear to have a risk low enough not to warrant high intensity treatment, that is, a survivor effect.
Our model did not consider cascade testing from children due to a lack of data on the effectiveness of statins in children. If children were included in the case-finding approach, this strategy is likely to become even more cost-effective as the number of relatives per index case would increase. A false-negative diagnosis may deny both the patient who has FH and that person"s relatives with FH the benefit of more intensive cholesterol lowering therapy. By contrast, cascade screening from false-positive cases will not identify any true FH patients and will waste resources. It would be possible to reduce the numbers of false positives and negatives if better data were available on the range of LDL-C levels to be expected in the mutation carrying relatives of patients with FH, and the extent to which this range overlaps with that in non-mutation carrying relatives.
Markov models have inherent limitations. They assume that the probability of an individual moving to any given health state in one time period depends only on their current health state (there is no longer "memory" in the model). Similarly, a patient"s health outcome and health care costs incurred are assumed to depend only on their current health state. These assumptions are unlikely to be strictly true, and will tend to underestimate the costs and overestimate the health outcomes for CVD events. Thus, interventions that prevent more CVD events will appear less cost-effective than they may be in reality.
Comparison with other studies Our results also compares favorably with strategies to identify individuals at a lower risk of cardiovascular disease (i.e. primary prevention), which were evaluated in a previous NICE 
Implications and future research
There is a lack of UK data describing the range of LDL-C levels to be expected in the mutation carrying relatives of patients with FH, and the extent to which this range overlaps with that in non-mutation carrying relatives. Further research is required to characterise the distributions of LDL-C levels in mutation-carrying relatives of patients with FH and the extent of overlap with levels in other relatives to improve the performance of screening strategies. The cost-effectiveness of DNA screening is likely to improve in the future as the proportion of definite FH patients in whom a mutation can be identified increases because of improvements in techniques for mutation identification, and also because of the identification of new genes where mutations cause FH. However, even now this economic analysis supports the identification and treatment of individuals with FH as a highly cost-effective strategy in the prevention of cardiovascular disease.
Conclusion
National strategies to reduce the burden of cardiovascular disease in the UK would be made more effective and more cost effective by incorporating the screening strategy that was recommended in national guidance from NICE for the identification and treatment of people with Familial Hypercholesterolemia. To date we are not aware that there has been any local implementation of such a strategy in England.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Familial Hypercholesterolaemia is a common genetic disorder where patients have a very high risk of early onset heart disease that can be effectively treated with high intensity statins.
Currently in the UK, less than 15% of the predicted 110,000 patients are diagnosed and there are no commissioned services to identify people with this condition. Clinical and cost effective strategies for the identification of patients with this condition and their implementation are urgently required.
WHAT THIS STUDY ADDS
Cascade testing from index patients with both clinically defined definite and possible FH is highly cost-effective when using a combination of DNA testing for the family mutation where it can be found and LDL-C levels where it cannot. Cascade testing to identify relatives of patients with FH is also more cost effective than recently recommended primary prevention screening strategies. The approach will become even more cost-effective as technological advances reduce the cost of DNA testing and increase its sensitivity and following the patent expiry of high intensity statins. 100.0% £500 £1,100 £1,700 £2,300 £2,900 £3,500 £4,100 £4,700 £5,300 £5,900 £6,500 £7,100 £7,700 £8,300 £8,900 £9,500 £10,100 £10,700 £11,300 £11,900 £12,500 £13,100 £13,700 £14,300 £14,900 £15,500 probability 
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Figure 1
Model structure, assumptions and analytical methods
We assumed that each index case has five first degree relatives available for testing 16 and each of these five has two first degree relatives (i.e. second degree relatives of the index case), and each of these has two first degree relatives (i.e. third degree relatives of the index case).
We also assumed that 65% of the first degree relatives and 60% of the second degree relatives will agree to be tested. These are high estimates for take up in population screening but are based on data from the UK FH Cascade Audit Project FHCAP S1 study where these values were 85% and 80% respectively. Finally, to simplify the model we assumed that 50% of the tested relatives would be the children of the probands and would be in the age range [18] [19] [20] [21] [22] [23] [24] [25] and the remainder would be the siblings of the probands, with an age range of 45-49 years.
We assumed that a monogenic cause underlies a diagnosis of FH, that is, a true FH patient is someone with a relevant gene mutation. To estimate the proportion of true FH patients in the hypothetical 1000 patients referred from general practice, we first used data from FHCAP S1 in which 30% of the patients currently being treated in lipid clinics had DFH and 60% had PFH while 10% failed to meet either set of criteria. This last group were designated true negative and not considered for cascade testing. Based on reported mutation detection rates, we then assumed that that 90% of those identified as DFH had a relevant gene mutation (were true FH), as well as 35% of those identified as PFH; meaning that 48% of our hypothetical cohort would be true FH patients ((0.9 x 0.3) +(0.35 x 0.6)) We are unaware of any published data to address this directly, and this is an extrapolation from the relative number of mutations identified in DFH and PFH patients (see below).
To estimate the proportion of FH and non-FH relatives that would be identified from true FH index cases with the cholesterol method of screening we used data from the UK 16 and the Netherlands 10 , which gave an age-averaged estimate of 32% true positives (i.e. had FH and were identified), 8% false positives (did not have FH but were identified as having FH), 42% true negatives, (did not have FH and were not identified as FH) and 18% false negatives (had FH but were not identified as FH) 10 . From false-positive index cases cascade testing will identify no true-positive relatives, but a proportion will be identified as "affected" (i.e. falsepositives) because they have LDL-C levels above the diagnostic cut-offs. Conversely, there will be no cascade screening from false negatives, so some true FH relatives will not be identified.
For the DNA strategy, the mutation detection rate was taken to be 80% in the DFH group and 30% in the PFH group 11, 12, 13 . Cascade testing only takes place from mutation-positive index cases and results in a 50% detection rate (since FH is a monogenic autosomal dominant disorder). However, since current mutation detection methods are not 100% sensitive, a proportion of the mutation-negative index cases will be false negatives. For the DFH group we assumed that this would be true of half of the 20% negatives in the DFH group, meaning that overall 80+10 = 90% of the DFH patients are true positives. For the PFH cases, it was assumed that a similar proportion of mutations would not be detected as in the DFH group (i.e. for every 8 mutations detected in the PFH group one would be missed so the false negative rate in the PFH patients with no detected mutation = 30% x 0.125 = 3.8 mutations per 100 patients), and an upper estimate of 7% of the PFH mutation-negative index cases as false negatives was used.
For the DNA+DFH strategy, as well as mutation positive index cases, cascade testing is additionally undertaken using cholesterol (LDL-C) diagnostic cut-offs in the 20% of patients in whom no mutation has been detected (DFH). The proportions of true-and false-positive diagnoses from this group were estimated as in the cholesterol method. Similarly, for the DNA+DFH+PFH strategy, cascade testing is undertaken using cholesterol (LDL-C) diagnostic cut-offs in the additional group of non-mutation-detected PFH index cases.
Treatment protocol and estimated long-term benefits from statin treatment.
All index cases and relatives with a diagnosis of FH (whether DFH or PFH) are assumed to be offered high intensity statin therapy, in line with NICE guideline on FH 14 . A proportion of those in the DNA-based strategies who do not carry the family mutation will qualify for low intensity statin treatment based on current NICE guidelines of having a >20% 10 year risk of age range, overall we predict that 1.3% 17 of relatives will qualify for low intensity statin.
We developed a Markov model using Microsoft™ Excel to estimate the treatment benefit from statins. The structure of the model is described in detail previously 18 . . Cost of DNA testing was £400 and £100 for probands and relatives respectively estimated from the FHCAP study (personal communication). All costs were at 2010/11 prices and as per current NICE guidance; an annual discount rate of 3.5% was used for both costs and health benefits.
Costs of DNA testing for Index cases and relatives were taken from FHCAP study. The costs included the costs of samples; postage in a provided blood-safe GPO recommended container and sending back the processed report to the referring clinicians (total estimated costs £20),
For index cases there are costs related to the three stage genetic testing , and for a detailed explanation of the procedures for the 3-stage genetic testing see S3 The three stages are: 1).
ARMS kit test of 20 common mutations, 2) Sequence of LDLR gene and 3) MLPA analysis England, 1996 The final utility for a health state was age adjusted by multiplying the health state utility with the age utility. For instance
Supplementary
In general those aged between 45-54 have a utility of 0.85 If the person has PAD the health state utility is 0.9 Therefore age adjusted utility in this case for a person with PAD would be (0.85*0.9)=0.765-this is the figure that will be used in the model 
